News related to
City

Hong Kong’s cross-boundary wealth rose 10.7% in 2025 to US$2.9 trillion, driven by Chinese Mainland flows and a vigorous stock market that delivered significant IPO (initial public offering) activity and strong gains in benchmark-heavy internet platforms, according to the report. It also projected that, from 2025 to 2030 the cross-boundary wealth managed by Hong Kong will grow by 9% on average annually and maintain first place globally, fully affirming Hong Kong’s position as a world-leading cross-boundary wealth management centre.

Paul Chan, Financial Secretary of the Hong Kong Special Administrative Region Government (HKSARG), highlighted that China’s National 15th Five-Year Plan clearly supports Hong Kong in strengthening its functions as an international asset and wealth management centre, which is also a key component of Hong Kong’s ‘Finance +’ development strategy.

“Over the past few years, the Government has worked closely with the financial sector to continuously improve the financial infrastructure and ecosystem, expand the range of investment products and risk management tools, and deepen the connectivity with capital markets around the world.

“Leveraging the advantages of ‘one country, two systems’, complemented by free, open, transparent, and predictable economic policies as well as a stable and secure investment environment, and cross-market connectivity, Hong Kong is attracting more and more ultra-high-net-worth individuals and family offices to establish a presence and invest in the city,” Mr Chan said.

Christopher Hui, Secretary for Financial Services and the Treasury of the HKSARG, noted that the Government had issued the Policy Statement on Developing Family Office Businesses in Hong Kong in March 2023 and has since implemented various measures to encourage family offices to operate in Hong Kong. Such initiatives, he said, include providing profits tax concession to family-owned investment holding vehicles managed by eligible single family offices and introducing the New Capital Investment Entrant Scheme.

“The Government will introduce legislative proposals into the Legislative Council next month (June 2026) to further enhance the preferential tax regimes for funds, single family offices and carried interest, so as to further enhance the competitiveness of the tax regimes, and attract more funds and family offices to set up and operate in Hong Kong,” Mr Hui said.

According to a study commissioned by Invest Hong Kong and published in February 2026, there were over 3,380 single family offices operating in Hong Kong as of end-2025, representing an increase of more than 25%, over the past two years.

Hashtag: #HongKong #BrandHongKong #Global #Wealth #Management #Top

https://www.brandhk.gov.hk/
https://www.linkedin.com/company/brand-hong-kong/
https://x.com/Brand_HK/
https://www.facebook.com/brandhk.isd
https://www.instagram.com/brandhongkong

The issuer is solely responsible for the content of this announcement.

Highlights of FY25/26 Results

HONG KONG SAR – Media OutReach Newswire – 28 May 2026 – Johnson Electric Holdings Limited (“Johnson Electric”), a global leader in electric motors and motion subsystems, today announced its results for the twelve months ended 31 March 2026.

Group sales for the 2025/26 financial year were US$3,650 million, an increase of 0.1% compared to the prior year. Net profit attributable to shareholders decreased by 23% to US$202 million or 21.59 US cents per share on a fully diluted basis. Adjusted net profit, excluding the effects of non-cash foreign exchange rate movements, the impairment of intangible assets, restructuring charges, and adverse fair value movements in investments, declined by 13% to US$234 million.

Sales Performance

The Automotive Products Group (“APG”) achieved sales of US$3,054 million, which amounted to 84% of total Group sales. Excluding currency effects, APG’s sales decreased by 3%.

Global automotive industry production volumes increased slightly over the prior year, but growth remains lacklustre in most markets due to affordability concerns and the challenges faced by OEMs and suppliers in adjusting to geopolitical uncertainty, tariff pressures, and the shifting economics of battery electric vehicles that continue to be shaped by the level of government subsidies available to consumers.

APG’s sales are divided broadly equally across the three major geographic regions of demand, but performance over the past year reflected distinct variations in local market conditions, as well as APG’s own mix of OEM customers and the timing of new program launches.

In Asia, the division’s sales declined by 7% on a constant currency basis primarily due to the ongoing erosion in market share held by Sino-foreign joint venture OEM customers in China. APG has continued to win significant new business awards from Chinese domestic OEMs and their suppliers, which now account for the majority of its sales in China. However, the division’s historically large share among joint venture customers has acted as a drag on its recent sales performance that is taking time to reverse. The domestic passenger vehicle market in China itself experienced a sharp slowdown in sales in the first quarter of 2026 due to the phasing out of trade-in subsidies designed to encourage the purchase of electric vehicles.

APG’s sales to the Americas increased by 1% on a constant currency basis in a market that saw total light vehicle production volumes broadly flat. The predominant factor constraining new car sales in North America is cost of living concerns, with many low to middle income car buyers struggling to afford new vehicles that, on average, have increased in price by over 30% since 2020.

In Europe, APG’s sales decreased by 2% on a constant currency basis. The European auto market continues to experience sluggish consumer demand at the same time that OEMs are hampered by excess production capacity and the impact of shifting emissions regulations on their product model line-ups.

APG’s strategy in the context of the varied and unpredictable operating environment for component suppliers is, firstly, to focus on bringing to market innovative motion technologies that enable electrification, reduce emissions, and enhance passenger safety and comfort. Secondly, APG aims to offer its diverse base of customers an unrivalled total cost and value proposition that combines speed, scale, and reliability of production with an adaptable global operating footprint.

The Industry Products Group (“IPG”) achieved sales of US$596 million – an increase of 2% compared to the prior year on a constant currency basis. After three successive years of declining sales, this marks an important return to growth for the division. In more commoditized product application segments, new business development has been redirected towards the rapidly growing base of Chinese manufacturers who are capturing an increasing share of the global market for consumer and commercial hardware goods – particularly for low-priced, entry-level products. In parallel, IPG is focused on supplying motion subsystem solutions to more specialized, higher-growth segments, including humanoid robotics, warehouse automation, medical devices, semiconductor manufacturing equipment, and liquid cooling applications.

Gross Margins and Operating Profitability

The Group’s gross profit of US$840 million, or 23.0% of sales, was essentially flat compared to the prior financial year. Slight increases in production staff costs, depreciation, and raw materials were offset by savings in other production overheads and direct labour.

Reported earnings before interest, tax and amortization (“EBITA”) amounted to US$258 million, a decrease of 22% compared to US$331 million achieved in the prior year. The decline was due to a combination of factors, including higher selling and administrative staff costs and other provisions, an impairment of intangible assets arising from a past acquisition, and reduced other income due to an adverse net change in the fair value of certain investments.

Net Profit and Financial Condition

Net profit attributable to shareholders decreased by 23% to US$202 million or 21.59 US cents per share on a fully diluted basis. Adjusted net profit, excluding the effects of non-cash foreign exchange rate movements, the impairment of intangible assets, restructuring charges, and adverse fair value movements in investments, amounted to US$234 million compared to US$268 million in the prior year.

The Group’s overall financial condition remains robust with a total debt to capital ratio of 10%, an interest coverage ratio of 22 times, and year-end cash reserves of US$902 million.

Dividends

The Board considers it appropriate to recommend maintaining the final dividend of 44 HK cents (5.64 US cents) per share, which together with the interim dividend of 17 HK cents per share, represents a total dividend of 61 HK cents (7.82 US cents) per share.

Chairman’s Comments on the Annual Results and Outlook

Commenting on the annual results for the financial year 2025/26, Dr. Patrick Wang, Chairman and Chief Executive, said, “Operating conditions for global manufacturing businesses during the financial year 2025/26 remained challenging, with end-market demand in most regions subdued and geopolitical events and uncertainties placing upward pressure on input costs.”

Dr. Patrick Wang further commented: “In the face of these headwinds, Johnson Electric maintained its long-standing resilience with sales and gross profit margins both holding up comparatively well. The bottom-line result, however, was negatively impacted by the effects of higher overhead expenses on a flat sales base, adverse net changes in the fair value of investments, and a non-cash intangible assets impairment charge.”

Concerning the near-term financial outlook, Dr. Patrick Wang said: “The global economy demonstrated resilience over the past year, despite the protracted conflict between Russia and Ukraine and the geopolitical shock of tariffs being imposed on US imports of goods from almost all countries. Looking ahead, the unstable and unpredictable conditions for trade and global manufacturing have been made even more precarious by the outbreak of war in the Middle East.”

“Johnson Electric has a long-standing track record in successfully navigating volatile global markets. In the near term, with geopolitical and macro-economic dynamics impossible to forecast with precision, management remains focused on cost control, managing the effects of inflation, and maintaining a prudent financial risk profile.”

“In parallel, however, we are also committed to invest in adapting and scaling our business model to meet strong underlying demand for our motion subsystem solutions in several high-growth end-markets and new product applications. Included among these are: thermal management systems for electric and hybrid vehicles that depend on a combination of water pumps, valves and actuators to support optimal vehicle cabin temperature, extend electric vehicle driving range, and contribute to longer battery life; solid oxide fuel cell power generation systems that are becoming established as an important source of low-emission, on-site electricity supply to AI data centres; and AI-enabled humanoid robots, which are widely viewed as one of the most significant industrial and commercial opportunities over the next ten to twenty years.”

Forward Looking Statements

This news release contains certain forward looking statements with respect to the financial condition, results of operations and business of Johnson Electric and certain plans and objectives of the management of Johnson Electric.

Words such as “outlook”, “expects”, “anticipates”, “intends”, “plans”, “believe”, “estimates”, “projects”, variations of such words and similar expressions are intended to identify such forward looking statements. Such forward looking statements involve known and unknown risk, uncertainties and other factors which may cause the actual results or performance of Johnson Electric to be materially different from any future results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding Johnson Electric’s present and future business strategies and the political and economic environment in which Johnson Electric will operate in the future.

Note to Editors and Securities Analysts: The full text of the Annual Results announcement, includingfinancial statements, is available through the Investors section of company’s website at www.johnsonelectric.com
Hashtag: #JohnsonElectric

The issuer is solely responsible for the content of this announcement.

About Johnson Electric Group

At Johnson Electric, our vision is to be the world’s definitive provider of innovation and reliable motion systems.

We are a global leader in electric motors, actuators, motion subsystems and related electro-mechanical components, serving a broad range of industries including Automotive, Liquid Cooling, Robotic Joints, Smart Metering, Business Equipment, Ventilation, Home Automation, Large Appliances, Power Tools, Medical Devices and Lawn & Garden Equipment. The Group is headquartered in Hong Kong and employes over 30,000 individuals in more than 20 countries worldwide. We are listed on The Stock Exchange of Hong Kong Limited ( Stock no. 179). For further information, please visit: www.johnsonelectric.com.

The resort, located on Naka Yai Island off Phuket’s east coast, has completed a series of enhancements designed to strengthen its appeal to affluent leisure travellers seeking privacy, wellness and destination-led experiences. The upgrades cover its Beachside Infinity Pool, villa interiors, spa facilities, restaurants, bar concepts and event spaces, reflecting a broader shift in Phuket’s luxury sector towards secluded, experience-rich stays rather than conventional beach resort offerings.

A central feature of the refresh is the transformed Beachside Infinity Pool, positioned against the Andaman Sea and redesigned as one of the resort’s main visual anchors. Its shape draws on Naka Yai Island and the resort’s own brand identity, while a new deck and cabana area add a stronger leisure component for guests using the beach and pool zones. The redesign gives the property a more defined social space without diluting its private-island positioning.

The villa upgrades are aimed at travellers prioritising seclusion and personal space. The resort has enhanced its private pool villas with updated interiors, bespoke furnishings and fully air-conditioned spa-style bathrooms. The emphasis on private pools in every villa aligns with demand from couples, families and long-haul guests who increasingly favour self-contained accommodation after the pandemic-era shift towards privacy-led luxury travel.

Spa Naka by HARNN has also been expanded from six to eight treatment rooms, adding capacity at a time when wellness remains one of the strongest growth areas in resort hospitality. The spa refresh includes replenished tropical gardens, upgraded pathways and new relaxation areas, reinforcing the property’s pitch as a wellness retreat rather than only a beach escape.

Dining has received equal attention. Aiyara, the resort’s signature restaurant, has been repositioned around Thai cuisine with design cues inspired by the elephant and the country’s cultural heritage. Veranda, the all-day dining venue, focuses on international menus in a beachfront setting, using natural materials such as reclaimed driftwood, rattan and pottery to reflect the surrounding marine environment. Rum Chapel offers Mediterranean flavours, seafood and imported premium ingredients, while Z Bar continues to serve as the sunset venue overlooking the Andaman.

The improvements come as Phuket’s luxury and upscale hotel market remains highly competitive, with resort operators seeking to differentiate through design, privacy, food and wellness. The island continues to attract travellers from Europe, the Middle East, Asia-Pacific and domestic markets, although Thailand’s broader tourism recovery has been uneven. Foreign arrivals rebounded strongly after border restrictions were lifted, but market composition has shifted, with softer Chinese demand and stronger competition from other regional destinations influencing pricing and occupancy.

Thailand welcomed nearly 33 million international visitors in 2025, below the previous year’s level but still among the strongest performances in Southeast Asia. Phuket remained one of the country’s most resilient destinations, supported by direct air links, villa-led accommodation, marine tourism and a mature luxury hospitality base. Upscale properties have benefited from travellers willing to spend more on privacy, wellness, curated activities and recognised hospitality standards.

The Michelin One Key recognition gives The Naka Island an additional credential in a crowded market. The Michelin hotel key system evaluates stays on criteria including architecture, character, service, comfort and value relative to the experience offered. Thailand’s 2025 selection included 62 key hotels, with The Naka Island listed among One Key properties, a category described as a very special stay. The distinction is expected to support international visibility, particularly among travellers who use independent hotel rankings to choose high-value resort stays.

The resort’s owner and operator ecosystem also adds weight to its positioning. The property is part of Marriott’s Luxury Collection portfolio, while The Erawan Group is associated with the asset as a hotel investor and operator in Thailand’s hospitality sector. The combination gives the resort access to global distribution, loyalty demand and professional asset management, while still allowing it to market itself around local identity and island seclusion.

Access remains central to the resort’s appeal. The property is reached by a short speedboat transfer from Phuket, creating a sense of separation while keeping it close to the island’s airport and main tourism infrastructure. Its location on Naka Yai allows the resort to market mangrove discovery, coastal activities, beach experiences and private dining as part of a contained luxury journey.

The ‘Xpress Sale’ is open for bookings from May 27 to May 31, 2026, with travel valid from June 15 to October 10. The discount applies to Lite and Value fare categories, giving passengers a wider window to plan summer, festive and early autumn trips across the carrier’s network. The airline began the sale through its website and mobile app on May 27, before widening access to major booking platforms from May 28.

The scale of the offer points to a calibrated push by Air India Express to fill capacity across a network that now spans 42 domestic and 17 international destinations. The carrier operates more than 500 daily flights and has been expanding its presence across South Asia, Southeast Asia and the Gulf, where demand is shaped by migrant traffic, family visits, business travel and holiday movement.

Passengers booking directly through the airline’s website or app during the sale are being offered zero convenience fees, adding a direct-channel incentive to the headline fare reduction. The campaign also includes additional benefits for Tata NeuPass members, including 20 per cent off Business Class fares, an extra discount of up to ₹300 on flight bookings and the opportunity to earn up to 8 per cent NeuCoins.

The Business Class offer covers seats with extra legroom, complimentary hot meals under the airline’s Gourmair product, enhanced check-in baggage allowance and priority services under Xpress Ahead. The airline is also offering up to 30 per cent off selected add-ons, including meals, seat selection, excess check-in baggage and extra cabin baggage options.

Air India Express is positioning the sale as both a demand-generation exercise and a customer-retention tool at a time when fare-sensitive travellers are comparing airlines more actively across direct platforms and online travel agencies. Promotional fare campaigns have become a central part of the low-cost aviation model, helping carriers improve forward bookings while encouraging passengers to buy optional services that raise ancillary revenue.

The offer arrives against a backdrop of steady aviation demand. Domestic air passenger traffic in FY2026 stood at about 167.7 million, reflecting moderate growth despite pressure from high operating costs and capacity adjustments across the sector. March 2026 alone recorded about 14.68 million domestic passengers, higher than both the previous month and the same month a year earlier.

Fuel remains one of the largest cost variables for airlines, often accounting for a major share of operating expenditure. Volatile jet fuel prices, currency pressure and airspace disruptions have added complexity to airline planning, making advance sales an important tool to manage load factors, cash flow and route economics. Discounted inventory can support demand on thinner routes while helping carriers protect aircraft utilisation during shoulder periods.

The campaign also fits into Air India Express’s broader transformation after the merger of AIX Connect with Air India Express was completed in October 2024. The merged low-cost carrier had a fleet of 88 aircraft at the time and has been working towards a larger narrow-body operation built around domestic and short-haul international markets.

The airline’s growth strategy includes a plan to more than double capacity over four to five years and build a fleet of more than 200 aircraft. Domestic routes are expected to take a larger share of capacity over time, rising towards about 60 per cent of operations, while short-haul international flying remains a key component of the network.

Gulf connectivity remains central to the carrier’s overseas strategy. Air India Express has been rebuilding and expanding services to West Asia, including Qatar, Bahrain, the UAE, Oman and Saudi Arabia, with more than 40 daily services to Gulf destinations after route resumptions and frequency additions. This market is especially important for travellers from Kerala, Karnataka, Tamil Nadu, Telangana and other states with deep labour, family and business links to the region.

During the conference, city officials reviewed the achievements of the “14th Five-Year Plan” period, noting that the progress made over the past five years has laid a solid foundation for the upcoming phase. The formulation of the new plan adhered to an open and inclusive approach, extensively incorporating feedback from various sectors of society. Following 36 rounds of revisions, the finalized document comprises 16 chapters and 77 sections, supported by 528 key projects designated for implementation.

The plan highlights five distinct features and centers on the comprehensive elevation of the city’s “Eight Qualities,” covering industrial development, innovation capacity, openness, ecological environment, cultural and humanistic development, public services, governance systems, and quality of life. Relevant officials further elaborated on key priorities, including the development of a modern industrial system, science and technology innovation-driven growth, advancement of new industrialization, implementation of the rural revitalization strategy, and optimization of public welfare and well-being.

Binzhou officials emphasized that the plan is not merely a policy document, but a strategic choice and action commitment for the city’s development toward 2030. Over the next five years, Binzhou is poised to fulfill its mission of “taking the lead and shouldering greater responsibilities.” Guided by the plan, the city will continue to exert effort in enhancing urban quality, driving innovation-led transformation, and improving public well-being, thereby writing a distinctive chapter of development within China’s broader journey toward modernization.

Hashtag: #BinzhouInformationOffice

The issuer is solely responsible for the content of this announcement.

Another significant step towards the success of ICVAX®

HONG KONG SAR – Media OutReach Newswire – 27 May 2026 – Immuno Cure Group (“Immuno Cure“), headquartered at Hong Kong Science Park, is pleased to announce the inauguration of the research facility for its HIV therapeutic DNA vaccine (“ICVAX^®“) at the Center of International Innovation for Technology and Science (“CIITS”) located in Hetao, Shenzhen. The facility aims for the development and application of key technologies for the clinical research and commercialization of Immuno Cure’s ICVAX^®. ICVAX^® is developed by Immuno Cure with the aim of achieving antiretroviral therapy (“ART“)-free functional cure for HIV infection. This project is carried out in collaboration with Prof. Zhiwei CHEN, the Founding Director of the AIDS Institute of Li Ka Shing Faculty of Medicine, the University of Hong Kong (“HKU AIDS Institute“), and Prof. Hongzhou LU, President of the Third People’s Hospital of Shenzhen, in the capacity as advisors.

CIITS is a national-level achievement transformation platform co-built by Guangdong Province, Shenzhen Municipality, and Tsinghua University, and is located at the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone (“Hetao Co-operation Zone“). It is committed to building a world’s leading major technological innovation and industrialization platform with a global perspective. It focuses on key tracks including biomedicine, high-performance materials, and artificial intelligence (AI). It aims to aggregate global innovation resources, connect with leading enterprises, and conduct organized scientific research and achievement transformation to address national major strategic needs.

Since AIDS was first identified in 1981, 40.8 million people have died from HIV infection, with over 44.1 million people living with HIV globally. While antiretroviral therapy can effectively control HIV replication, it cannot cure the disease, highlighting the critical need for immunotherapies. Designed to enhance the host’s immune response, immunotherapies aim to achieve sustained viral control without lifelong ART, ultimately leading to complete viral suppression and functional cure. Immuno Cure’s proprietary innovative HIV therapeutic DNA vaccine, ICVAX^®, induces broad-spectrum, polyfunctional virus-specific T cells to achieve the ultimate goal of ART-free functional cure of HIV infection.

Immuno Cure completed the first-in-human Phase I clinical trial of ICVAX^® in November 2024, demonstrating excellent safety and promising immunogenicity. Two multi-center Phase II clinical trials—randomized, double-blind, and placebo-controlled—are scheduled to launch in Q2-2026 to evaluate the vaccine’s mechanism of action and efficacy. The trials will be conducted at Prince of Wales Hospital in Hong Kong, as well as eight top-tier hospitals in China, including the Shenzhen Third People’s Hospital, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing Youan Hospital affiliated to Capital Medical University, the Eighth People’s Hospital of Guangzhou, the Second People’s Hospital of Tianjin, the Sixth People’s Hospital of Zhengzhou, Chengdu Public Health Clinical Medical Center, and Chongqing Public Health Medical Center.

Notably, standardized testing systems for evaluating immunological and virological indicators are crucial for HIV vaccine clinical trials. However, the lack of domestic standard operating procedures (SOPs) for infectious samples in clinical trials hinders the clinical development and regulatory approval of novel infectious disease therapies like ICVAX^®. The mission of this research facility at CIITS is to establish an internationally aligned standardized clinical testing system for T-cell immunogenicity and viral reservoirs, as well as identify core biomarkers associated with vaccine efficacy — filling a domestic technical gap. Immuno Cure will offer the ICVAX^® Phase II clinical trial to facilitate the development of this standardized precision testing method for clinical sample analysis.

Dr. Xia JIN, CEO of Immuno Cure, stated, “I am delighted to be appointed to lead this key project of CIITS. I would also like to thank CIITS for the fully fitted modern laboratory space and the RMB10.0m funding support for this 2-year initial phase. My whole scientific team is committed to contributing diligently to the success of this project. I have no doubt that the development of a standardised testing regime would not only enhance the quality of our clinical trials for ICVAX^® but would also eventually be adopted as industry and national standards for the clinical translation of medicine for HIV/AIDS and other infectious diseases.

Renchen LIU, Executive Deputy Dean of Research Institute of Tsinghua University in Shenzhen and Director of CIITS, stated, “Warmest congratulations on the inauguration of the research facility for ICVAX^® at the CIITS. In the future, CIITS will continue to leverage its platform resources to implement full-chain incubation services. Project managers will provide service support throughout the entire project period, ensuring the smooth progress of the project through resource integration, talent recruitment and development, clinical collaboration, and achievement transformation. These efforts will safeguard the steady progress of the project.”

As the project advances, Immuno Cure’s ICVAX^® is positioned to become the world’s first therapeutic DNA vaccine to deliver an ART-free functional cure for HIV infection, bringing new hope to people currently living with HIV. In parallel, the standardized testing platform and collaborative innovation model developed through this effort will provide a scalable, replicable blueprint for R&D of novel therapies targeting other major infectious diseases. Together, these outcomes will strengthen the global competitiveness of biomedicine development in GBA and contribute to the development of national biosecurity capabilities and a more resilient public health system.

Hashtag: #ImmunoCure

https://immunocure.hk
https://www.linkedin.com/company/immuno-cure

The issuer is solely responsible for the content of this announcement.

About the Center of International Innovation for Technology and Science (“CIITS”)

Center of International Innovation for Technology and Science (CIITS), as the international headquarter of the Greater Bay Area National Center of Technology Innovation (GBA NCTI), is operated by Research Institute of Tsinghua University in Shenzhen (RITS). CIITS actively promotes the commercialization of technology and scientific advances with overseas and domestic innovation institutions and teams, as well as industry partners, focusing on areas such as biomedicine, advanced materials and artificial intelligence.

To learn more about CIITS, please follow the WeChat official account: gh_425f503135d5

About Immuno Cure

Immuno Cure is a clinical-stage biotechnology group headquartered at Hong Kong Science Park. Immuno Cure is committed to the R&D of innovative DNA vaccines and antibody immunotherapies for infectious diseases, inflammations, and cancers. Immuno Cure possesses two technologies: the “PD-1 Enhanced DNA Vaccine Platform” and the “Anti-Δ42PD1 Antibody”.

To learn more about Immuno Cure, please visit: www.immunocure.hk

Asia’s first Design & Innovation Festival announces its venue and key speakers — where Japanese design expertise meets the cultural diversity of Asia

BANGKOK, THAILAND – Media OutReach Newswire – 27 May 2026 – On Friday, June 26, 2026, SYNC Design & Innovation in SITE 2026 will be held at Siam Paragon, Bangkok — a large-scale forum dedicated to the convergence of design and business. Organized by Nikkei Business Publications, Inc. (Nikkei BP) and co-organized by FOURDIGIT Inc. and the National Innovation Agency (NIA) of Thailand, the event announces its venue and principal speaker lineup.

Hashtag: #FOURDIGIT

The issuer is solely responsible for the content of this announcement.